Synthesis and in vitro antitubercular activity of pyridine analouges against the resistant Mycobacterium tuberculosis

Area of Science:

• Medicinal Chemistry
• Microbiology
• Drug Discovery

Background:

• Tuberculosis (TB) poses a significant global health challenge, exacerbated by the rise of multi-drug resistant strains (MDR-TB).
• Isoniazid (INH) resistance in Mycobacterium tuberculosis (MTB) necessitates the development of novel analogs to combat resistant infections.

Purpose of the Study:

• To synthesize and evaluate novel isoniazid and pyridine derivatives for antimycobacterial activity.
• To identify compounds effective against drug-resistant Mycobacterium tuberculosis strains.

Main Methods:

• Synthesis of isoniazid and pyridine derivatives.
• Characterization of synthesized compounds using spectral data.
• Assessment of antimycobacterial activity via IC50 and Minimum Inhibitory Concentration (MIC) assays against MTB H37Rv and drug-resistant isolates.

Main Results:

• Compounds 1 and 2 demonstrated potent antimycobacterial activity against the H37Rv strain with IC50 values of 3.2 µM and 1.5 µM, respectively.
• Both compounds exhibited significant activity against various drug-resistant MTB isolates (FQ-R1, INH-R1, INH-R2, RIF-R1, RIF-R2) at non-cytotoxic concentrations.
• Compound 2 showed particularly strong activity against RIF-R1 (MIC = 1.8 µM) and Compound 1 against RIF-R2 (MIC = 4.2 µM).

Conclusions:

• The synthesized isoniazid and pyridine derivatives show potential as novel therapeutic agents against drug-susceptible and drug-resistant tuberculosis.
• Compounds 1 and 2 represent promising leads for further development into effective treatments for MDR-TB.